Table 1. Therapeutic monoclonal antibodies approved in the US

Generic name

Trade name

Type

Indication first approved

FDA approval year

Muromonab-CD3

Orthoclone Okt3

Murine IgG2a

Reversal of kidney transplant rejection

1986

Abciximab

Reopro

Chimeric IgG1 Fab

Prevention of blood clots in angioplasty

1994

Rituximab

Rituxan

Chimeric IgG1

Non-Hodgkin lymphoma

1997

Daclizumab

Zenapax

Humanized IgG1

Prevention of kidney transplant rejection

1997

Basiliximab

Simulect

Chimeric IgG1

Prevention of kidney transplant rejection

1998

Palivizumab

Synagis

Humanized IgG1

Prevention of respiratory syncytial virus infection

1998

Infliximab

Remicade

Chimeric IgG1

Crohn disease

1998

Trastuzumab

Herceptin

Humanized IgG1

Breast cancer

1998

Gemtuzumab ozogamicin

Mylotarg

Humanized IgG4

Acute myeloid leukemia

2000

Alemtuzumab

Campath-1H

Humanized IgG1

Chronic myeloid leukemia

2001

Ibritumomab tiuxetan

Zevalin

Murine IgG1

Non-Hodgkin lymphoma

2002

Adalimumab

Humira

Human IgG1

Rheumatoid arthritis

2002

Omalizumab

Xolair

Humanized IgG1

Asthma

2003

Tositumomab-I131

Bexxar

Murine IgG2a

Non-Hodgkin lymphoma

2003

Efalizumab

Raptiva

Humanized IgG1

Psoriasis

2003*

Cetuximab

Erbitux

Chimeric IgG1

Colorectal cancer

2003

Bevacizumab

Avastin

Humanized IgG1

Colorectal cancer

2004

Natalizumab

Tysabri

Humanized IgG4

Multiple sclerosis

2004

Ranibizumab

Lucentis

Humanized IgG1

Fab

Macular degeneration

2006

Panitumumab

Vectibix

Human IgG2

Colorectal cancer

2006

Eculizumab

Soliris

Humanized IgG2/4

Paroxysmal nocturnal hemoglobinuria

2007

Certolizumab
pegol

Cimzia Humanized Fab Crohn disease 2008
Golimumab Simponi Human IgG1 Rheumatoid and psoriatic arthritis, ankylosing spondylitis 2009

*Voluntarily withdrawn from US market in April 2009
Source: Tufts Center for the Study of Drug Development